Angiotech Pharmaceuticals ( ANPI) fell 5.6% after it reported disappointing third-quarter results and said its full-year financials will likely fall short of estimates.

The company reported revenue of $86.3 million, mostly from its medical-products segment and royalty revenue, in the third quarter. Analysts surveyed by Thomson First Call were expecting $95.9 million. Angiotech earned $6.9 million, or 9 cents a share, but excluding charges, it would have had a profit of 19 cents. Still, analysts were looking for 20 cents a share.

Additionally, Angiotech reduced its full-year earnings and revenue guidance, partly because of costs it expects to incur in the fourth quarter for product development, sales and marketing. The company now sees a profit of 70 cents to 72 cents a share for 2006, down from its old projection of 79 cents to 81 cents a share.

The company expects to report revenue of $302 million to $306 million vs. its previous estimate of $325 million to $335 million. Product sales are expected to be $138 million to $140 million for the full year. Angiotech previously anticipated $155 million to $163 million.

Shares of Angiotech were slumping 53 cents to $8.97.

Allergan ( AGN), the company that makes the wrinkle treatment Botox, slipped after saying its earnings took a hit from rising expenses during the latest quarter. Adjusted profits still managed to beat Wall Street's estimates.

The company earned $106.4 million, or 70 cents a share, in the third quarter, down from $150.5 million, or $1.12 a share, a year ago. The most recent quarter includes expenses related to the acquisition of breast-implant manufacturer Inamed earlier this year. Excluding charges, Allergan earned 95 cents a share, a penny above analysts' estimates.

Allergan's revenue reached $806.8 million in the third quarter, with product sales coming in at $791.7 million, including $116.3 million from Inamed. The company's Botox and neuromodulator segment had sales of $237.7 million, up from $214.8 million a year ago. Eye-care pharmaceuticals brought in $403.4 million, up from $358.1 million the previous year. Analysts were expecting the company to report revenue of $784.2 million.

For all of 2006, Allergan expects to report sales of between $2.98 billion and $3.02 billion, excluding revenue from the former Inamed products. Allergan previously expected to report full-year product sales of between $2.87 billion and $3.01 billion. Shares fell $3.07 to $112.43.

Beckman Coulter ( BEC), a manufacturer of biomedical-testing instruments and supplies, gained 3.3% after its third-quarter earnings rose more than 30% from the year-ago period.

The company earned $47.4 million, or 74 cents a share, in the quarter, compared with $36.2 million, or 56 cents a share, a year ago. Adjusted for items, earnings were 66 cents a share in the most recent quarter, in line with analysts' estimation.

Third-quarter revenue rose 6.4% from a year ago to $631.2 million. Analysts surveyed by Thomson First Call were expecting revenue of $622.2 million. Revenue from worldwide consumables rose 13.7% in the most recent quarter.

Beckman expects to earn $2.75 a share to $2.95 a share, excluding special items, for the year. On average, analysts are looking for $2.83 a share. Shares were up $1.90 to $59.47.

Mylan Laboratories ( MYL) issued second-quarter results that topped expectations thanks primarily to a painkiller that accounted for about 20% of sales.

Still, shares edged lower by 17 cents to $20.33.

The generic-drug company earned 37 cents a share, excluding one-time items, on sales of $366.7 million for the three months ended Sept. 30. The consensus among analysts polled by Thomson First Call predicted an EPS of 32 cents and sales of $350.8 million.

On a GAAP basis, Mylan earned $77.5 million, or 36 cents a share, compared to $35.8 million, or 16 cents a share, for the same period last year. Sales for the year-ago quarter were $298 million.

Mylan kept its fiscal-year profit forecast of $1.35 to $1.55, excluding one-time items. The average Wall Street estimate is $1.30 for the year ending March 31, 2007.

More from Investing

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Podcast: What TheStreet's Interns Learned From Jim Cramer and Action Alerts PLUS

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Bank of America, Tariffs and the Goldman Sachs CEO Change: Jim Cramer Rewind

Alphabet Reports Earnings on Monday: 5 Things to Watch

Alphabet Reports Earnings on Monday: 5 Things to Watch

General Electric's Other Big Concern Besides Its Challenged Power Unit

General Electric's Other Big Concern Besides Its Challenged Power Unit

Goldman Sachs Really Doesn't Like Apple's Stock

Goldman Sachs Really Doesn't Like Apple's Stock